These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23035722)

  • 21. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis.
    Pal I; Rajesh Y; Banik P; Dey G; Dey KK; Bharti R; Naskar D; Chakraborty S; Ghosh SK; Das SK; Emdad L; Kundu SC; Fisher PB; Mandal M
    Cancer Lett; 2019 Jun; 452():254-263. PubMed ID: 30904616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRas(Q61K) ; Cdkn2a(-/-) transgenic mice.
    Campagne C; Reyes-Gomez E; Battistella M; Bernex F; Château-Joubert S; Huet H; Beermann F; Aubin-Houzelstein G; Egidy G
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):735-42. PubMed ID: 23647911
    [No Abstract]   [Full Text] [Related]  

  • 24. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
    Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
    Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
    VanBrocklin MW; Robinson JP; Lastwika KJ; Khoury JD; Holmen SL
    Pigment Cell Melanoma Res; 2010 Aug; 23(4):531-41. PubMed ID: 20444198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
    Gallagher SJ; Thompson JF; Indsto J; Scurr LL; Lett M; Gao BF; Dunleavey R; Mann GJ; Kefford RF; Rizos H
    Neoplasia; 2008 Nov; 10(11):1231-9. PubMed ID: 18953432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment.
    Coleman DJ; Chagani S; Hyter S; Sherman AM; Löhr CV; Liang X; Ganguli-Indra G; Indra AK
    Mol Cancer Res; 2015 Jan; 13(1):186-96. PubMed ID: 25189354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth.
    Andreu-Pérez P; Hernandez-Losa J; Moliné T; Gil R; Grueso J; Pujol A; Cortés J; Avila MA; Recio JA
    BMC Cancer; 2010 Jun; 10():265. PubMed ID: 20529342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.
    Chin L; Pomerantz J; Polsky D; Jacobson M; Cohen C; Cordon-Cardo C; Horner JW; DePinho RA
    Genes Dev; 1997 Nov; 11(21):2822-34. PubMed ID: 9353252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.
    Dovey M; White RM; Zon LI
    Zebrafish; 2009 Dec; 6(4):397-404. PubMed ID: 19954345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.
    Mathieu V; Pirker C; Schmidt WM; Spiegl-Kreinecker S; Lötsch D; Heffeter P; Hegedus B; Grusch M; Kiss R; Berger W
    Oncotarget; 2012 Apr; 3(4):399-413. PubMed ID: 22535842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
    J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism.
    Li A; Ma Y; Jin M; Mason S; Mort RL; Blyth K; Larue L; Sansom OJ; Machesky LM
    J Invest Dermatol; 2012 Nov; 132(11):2610-21. PubMed ID: 22718121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pathway ahead in melanoma trials.
    Miller AJ; Markovic SN; Haluska P
    Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
    [No Abstract]   [Full Text] [Related]  

  • 40. Progression of NRAS and BRAF mutations in cutaneous melanoma.
    Rosso R; Romagosa Y; Kirsner RS
    J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.